An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma
Study Status
Open to Enrollment
Study Description
This clinical trial is for men and women with refractory follicular lymphoma who:
- Have received at least 2 prior lines of therapy, and
- Did not respond to the last prior therapy
The purpose of the study is to evaluate the response to treatment with an experimental drug called ibrutinib, also called PCI-32765.
Ibrutinib is an oral drug that inhibits the enzyme Bruton’s Tyrosine Kinase (BTK), decreasing the ability of lymphoma cells to grow and survive.
All study participants will receive ibrutinib; there is no placebo. Participants will take 4 capsules by mouth once every day. Participants will continue taking ibrutinib as long as they are responding to treatment and not experiencing unacceptable side effects.
Follow the Weill Cornell Lymphoma Program Online:
Blog: cornell-lymphoma.com
Facebook: www.facebook.com/lymphomaprogram
Twitter: @lymphomaprogram
Disease Status and/or Stage
Refractory Follicular Lymphoma
Sponsor
Janssen
Key Eligibility
- Age 18 and older
- Refractory follicular lymphoma
- Previously treated with at least 2 prior lines of therapy
- Did not respond to last prior therapy
- Detailed eligibility reviewed when you contact the study team
Principal Investigator
Contact
- Amelyn Rodriguez, RN
- (212) 746-1362
- [email protected]
- Weill Cornell Lymphoma Center
- (646) 962-2700
Protocol ID
PCI-32765FLR2002
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
